Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Non-Current Assets (2023 - 2025)

CG Oncology filings provide 3 years of Non-Current Assets readings, the most recent being $32.1 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 5371.38% to $32.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $121.6 million, a 6163.85% increase, with the full-year FY2025 number at $32.1 million, up 5371.38% from a year prior.
  • Non-Current Assets hit $32.1 million in Q4 2025 for CG Oncology, down from $34.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $34.1 million in Q3 2025 to a low of $391000.0 in Q3 2024.
  • Median Non-Current Assets over the past 3 years was $5.2 million (2023), compared with a mean of $14.3 million.
  • Biggest five-year swings in Non-Current Assets: plummeted 88.66% in 2024 and later soared 8627.11% in 2025.
  • CG Oncology's Non-Current Assets stood at $5.2 million in 2023, then plummeted by 88.66% to $587000.0 in 2024, then surged by 5371.38% to $32.1 million in 2025.
  • The last three reported values for Non-Current Assets were $32.1 million (Q4 2025), $34.1 million (Q3 2025), and $28.4 million (Q2 2025) per Business Quant data.